Apolipoprotein D modulates arachidonic acid signaling in cultured cells: Implications for psychiatric disorders

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 69, Issue 6, 2003, Pages 421-427

  Thomas, Elizabeth A ^a   George, Roshni C ^a   Gregor Sutcliffe, J ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Apolipoprotein; Arachidonic acid; Clozapine; Expression; Fatty acid; Phospholipase A2; Schizophrenia; Signalling

Indexed keywords

APOLIPOPROTEIN D; ARACHIDONIC ACID; MEMBRANE PHOSPHOLIPID; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; EMBRYO; EMBRYO CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CELL; MENTAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

EID: 0344441346     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2003.08.014     Document Type: Article

References (44)

1. E.A. Thomas, S.M. Laws, J.G. Sutcliffe, C. Harper, B. Dean, C. McClean, C. Masters, N. Lautenschlager, S.E. Gandy, R.N. Martins, Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relation to apolipoprotein e expression or genotype, Biol. Psychiat. 54 (2003) 136-141.
2. B. Belloir, E. Kovari, M. Surini-Demiri, A. Savioz, Altered apolipoprotein D expression in the brain of patients with Alzheimer disease, J. Neurosci. Res. 64 (1) (2001) 61-69.
3. J. Kalman, W. McConathy, C. Araoz, P. Kasa, A. Lacko, Apolipoprotein D in the aging brain and in Alzheimer's dementia, Neurol. Res. 22 (2000) 330-336.
4. L. Terrisse, J. Poirier, P. Bertrand, A. Merched, S. Visvikis, G. Siest, R. Milne, E. Rassart, Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients, J. Neurochem. 71 (1998) 1643-1650.
5. E.A. Thomas, B. Dean, G. Pavey, J.G. Sutcliffe, Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders, Proc. Natl. Acad. Sci. USA 98 (7) (2001) 4066-4071.
6. E.A. Thomas, B. Dean, E. Scarr, D. Copolov, J.G. Sutcliffe, Differences in neuroanatomical sites of ApoD elevation discriminate schizophrenia and bipolar disorder, Molec. Psychiat. 8 (2003) 168-176.
7. S.P. Mahadik, M.M. Khan, D.R. Evans, V.V. Parikh, Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome, Schizophr. Res. 58 (1) (2002) 55-62.
8. E.A. Thomas, P.E. Danielson, P.A. Nelson, T.M. Pribyl, B.S. Hilbush, K.W. Hasel, J.G. Sutcliffe, Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy, J. Neurochem. 76 (2001) 789-796.
9. J.K. Boyles, L.M. Notterpek, L.J. Anderson, Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E and apolipoprotein A-I, J Biol. Chem. 265 (1990) 17805-17815.
10. W.Y. Ong, Y. He, S. Suresh, S.C. Patel, Differential expression of apoliprotein D and apoliprotein E in the kainic acid-lesioned rat hippocampus, Neuroscience 79 (1997) 359-367.
11. L. Terrisse, D. Sequin, P. Bertrand, J. Poirier, R. Milne, E. Rassart, Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion, Brain Res. Mol. Brain Res. 70 (1999) 26-35.
12. E. Rassart, A. Bedirian, S. Do Carmo, O. Guinard, J. Sirois, L. Terrisse, R. Milne, Apolipoprotein D, Biochim. Biophys. Acta 18 (2000) 1-2.
13. W.G. Dilley, D.E. Haagensen, C.E. Cox, S.A. Wells, Immunologic and steroid binding properties of CDFP-24 protein isolated from human breast gross cystic disease fluid, Breast Cancer Res. Treat. 16 (1990) 253-260.
14. O.A. Lea, Binding properties of progesterone-binding cyst protein PBCP, Steroids 52 (1988) 337-338.
15. W.H. Pearlman, J.L. Gueriguian, M.E. Sawyer, A specific progesterone-binding component of human breast cyst fluid, J. Biol. Chem. 248 (16) (1973) 5736-5741.
16. M.C. Peitsch, M.S. Boguski, Is apolipoprotein D a mammalian bilin-binding protein?, New Biol. 2 (2) (1990) 197-206.
17. C. Zeng, A.I. Spielman, B.R. Vowels, J.J. Leyden, K. Biemann, G. Preti, A human axillary odorant is carried by apolipoprotein D, Proc. Natl. Acad. Sci. USA 93 (13) (1996) 6626-6630.
18. J.H. Morais-Cabral, G.L. Atkins, L.M. Sanchez, Y.S. Lopez-Boado, C. Lopez-Otin, L. Sawyer, Arachidonic acid binds to apoliprotein D: implications for the protein's function, FEBS Lett. 366 (1995) 53-56.
19. M. Vogt, A. Skerra, Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E-3M2H, J. Mol. Recog. 14 (1) (2001) 79-86.
20. L. Demisch, K. Heinz, H. Gerbaldo, R. Kirsten, Increased concentrations of phosphatidylinositol (PI) and decreased esterification of arachidonic acid into phospholipids in platelets from patients with schizoaffective disorders or atypic phasic psychoses, Prostaglandins Leukot. Essent. Fatty Acids 46 (1992) 47-52.
21. A.I. Glen, E.M. Glen, D.F. Horrobin, K.S. Vaddadi, M. Spellman, N. Morse-Fisher, K. Ellis, F.S. Skinner, A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases, Schizophr. Res. 12 (1) (1994) 53-61.
22. S.P. Mahadik, S. Mukherjee, E.E. Correnti, H.S. Kelkar, C.G. Wakade, R.M. Costa, R. Scheffer, Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis, Schizophr. Res. 13 (1994) 239-247.
23. S.P. Mahadik, S. Mukherjee, D.F. Horrobin, K. Jenkins, E.E. Correnti, R. Scheffer, Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects, Psychiatry Res. 63 (1996) 133-142.
24. M. Peet, J.D. Laugharne, J. Mellor, C.N. Ramchand, Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation, Prostaglandins Leukot. Essent. Fatty Acids 55 (1996) 71-75.
25. J.K. Yao, D.P. van Kammen, J.A. Gurklis. Abnormal incorporation of arachidonic acid into latelets of drug-free patients with schizophrenia, Psychiatry Res. 60 (1996) 11-21.
26. J.K. Yao, S. Leonard, R.D. Reddy, Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients, Schizophr. Res. 42 (1) (2000) 7-17.
27. B.K. Puri, S.R. Hirsch, T. Easton, A.J. Richardson, A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia, Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (1) (2002) 49-52.
28. S.H. Shah, G.K. Vankar, M. Peet, C.N. Ramchand, Unmedicated schizophrenic patients have a reduced skin flush in response to topical niacin, Schizophr. Res. 43 (2-3) (2000) 163-164.
29. P.E. Ward, J. Sutherland, E.M. Glen, A.I. Glen, Niacin skin flush in schizophrenia: a preliminary report, Schizophr. Res. 29 (3) (1998) 269-274.
30. 2 superfamily of signal transduction enzymes, Trends Biochem. Sci. 22 (1) (1997) 1-2.
31. 2 activity in schizophrenic patients: reduction after neuroleptic therapy, Biol. Psychiatry 22 (1987) 421-426.
32. 2, Arch. Gen. Psychiatry 54 (1997) 487-494.
33. 2 activities in brain of patients with schizophrenia, Brain Res. 821 (1999) 407-413.
34. 2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages, Proc. Natl. Acad. Sci. USA 92 (18) (1995) 8527-8531.
35. 2 on short chain phosphatidylcholine-mixed micelles: development of a spectrophotometric assay suitable for a microtiterplate reader, Anal. Biochem. 204 (1) (1992) 190-197.
36. P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, E.K. Fujimoto, N.M. Goeke, B.J. Olson, D.C. Klenk, Measurement of protein using bicinchoninic acid, Anal. Biochem. 150 (1) (1985) 76-85.
37. 2 enzymes, Proc. Natl. Acad. Sci. USA 91 (23) (1994) 11060-11064.
38. S.C. Patel, K. Asotra, Y.C. Patel, W.J. McConathy, R.C. Patel, S. Suresh, Astrocytes synthesize and secrete the lipophilic ligand carrier apolipoprotein D, Neuroreport 6 (1995) 653-657.
39. A. Lin, G. Kenis, S. Bignotti, G.J. Tura, R. De Jong, E. Bosmans, R. Pioli, C. Altamura, S. Scharpe, M. Maes, The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6, Schizophr. Res. 32 (1) (1998) 9-15.
40. J.K. Yao, R.D. Reddy, D.P. van Kammen, Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications, CNS Drugs 15 (4) (2001) 287-310.
41. D.F. Horrobin, A.I.M. Glen, R.C. Cantrill, Clozapine: elevation of membrane unsaturated lipid levels as a new mechanism of action, Schizophr. Res. 24 (1997) 214.
42. M. Peet, D.F. Horrobin, A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms, J. Psychiatr. Res. 36 (1) (2002) 7-18.
43. D.F. Horrobin, K. Jenkins, C.N. Bennett, W.W. Christie, Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding, Prostaglandins Leukot. Essent. Fatty Acids 66 (1) (2002) 83-90.
44. A.J. Richardson, T. Easton, B.K. Puri, Red cell and plasma fatty acid changes accompanying symptom remission in a patient with schizophrenia treated with eicosapentaenoic acid, Eur. Neuropsychopharmacol. 10 (3) (2000) 189-193.